ARTEMIS-003: A Phase 2, Open-label, Multi-center Study to Evaluate Efficacy, Safety, and Pharmacokinetics, of Intravenous Administration of HS-20093 in Patients With Metastasis Castration Resistant Prostate Cancer and Advanced Solid Tumors Who Have Progressed Following at Least One Prior Therapy
Latest Information Update: 22 Aug 2024
At a glance
- Drugs HS-20093 (Primary)
- Indications Prostate cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms ARTEMIS-003
- Sponsors Hansoh BioMedical R&D Company
Most Recent Events
- 26 Feb 2024 Status changed from not yet recruiting to recruiting.
- 24 Aug 2023 New trial record